Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial
JR Mackey, M Martin, T Pienkowski, J Rolski… - The Lancet …, 2013 - thelancet.com
Background We compared standard adjuvant anthracycline chemotherapy with
anthracycline–taxane combination chemotherapy in women with operable node-positive …
anthracycline–taxane combination chemotherapy in women with operable node-positive …
Risk of cardiometabolic risk factors in women with and without a history of breast cancer: the pathways heart study
ML Kwan, RK Cheng, C Iribarren… - Journal of clinical …, 2022 - ascopubs.org
PURPOSE The incidence of cardiometabolic risk factors in breast cancer (BC) survivors has
not been well described. Thus, we compared risk of hypertension, diabetes, and …
not been well described. Thus, we compared risk of hypertension, diabetes, and …
Breast cancer therapy–related cardiac dysfunction in adult women treated in routine clinical practice: a population-based cohort study
P Thavendiranathan, H Abdel-Qadir… - Journal of Clinical …, 2016 - ascopubs.org
Purpose Most women diagnosed with breast cancer are younger than 65 years of age.
Population-based studies on cancer therapy–related cardiotoxicity have focused on older …
Population-based studies on cancer therapy–related cardiotoxicity have focused on older …
Cancer chemotherapy and cardiac arrhythmias: a review
Cardiovascular toxicity is a potential complication of cancer chemotherapy (CC) that
increases the morbidity and mortality of cancer patients. Cardiac arrhythmias have been …
increases the morbidity and mortality of cancer patients. Cardiac arrhythmias have been …
Alteration of topoisomerase II–alpha gene in human breast cancer: Association with responsiveness to anthracycline-based chemotherapy
MF Press, G Sauter, M Buyse, L Bernstein… - Journal of Clinical …, 2011 - ascopubs.org
Purpose Approximately 35% of HER2-amplified breast cancers have coamplification of the
topoisomerase II-alpha (TOP2A) gene encoding an enzyme that is a major target of …
topoisomerase II-alpha (TOP2A) gene encoding an enzyme that is a major target of …
Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for …
AL Jones, M Barlow, PJ Barrett-Lee, PA Canney… - British journal of …, 2009 - nature.com
More women are living with and surviving breast cancer, because of improvements in breast
cancer care. Trastuzumab (Herceptin®▾) has significantly improved outcomes for women …
cancer care. Trastuzumab (Herceptin®▾) has significantly improved outcomes for women …
New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients
M Ryberg, D Nielsen, G Cortese… - Journal of the …, 2008 - academic.oup.com
Background Current recommendations that cancer patients receive a maximum cumulative
dose of 900 mg/m2 epirubicin are based on the risk of epirubicin-mediated cardiotoxicity …
dose of 900 mg/m2 epirubicin are based on the risk of epirubicin-mediated cardiotoxicity …
Doxorubicin inactivates myocardial cytochrome c oxidase in rats: cardioprotection by Mito-Q
K Chandran, D Aggarwal, RQ Migrino, J Joseph… - Biophysical …, 2009 - cell.com
Doxorubicin (DOX) is used for treating various cancers. Its clinical use is, however, limited by
its dose-limiting cardiomyopathy. The exact mechanism of DOX-induced cardiomyopathy …
its dose-limiting cardiomyopathy. The exact mechanism of DOX-induced cardiomyopathy …
Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with …
MC Arciniegas Calle, NP Sandhu, H Xia, SS Cha… - BMC cancer, 2018 - Springer
Background Combined anthracycline-trastuzumab chemotherapy has been associated with
LV dysfunction. We aimed to assess early changes in left ventricular (LV) and right …
LV dysfunction. We aimed to assess early changes in left ventricular (LV) and right …
The role of iron in doxorubicin-induced cardiotoxicity: recent advances and implication for drug delivery
Y Qin, T Guo, Z Wang, Y Zhao - Journal of Materials Chemistry B, 2021 - pubs.rsc.org
As an anthracycline antibiotic, doxorubicin (DOX) is one of the most potent and widely used
chemotherapeutic agents for treating various types of tumors. Unfortunately, the clinical …
chemotherapeutic agents for treating various types of tumors. Unfortunately, the clinical …